

## SynAct Pharma to present at the BioStock Global Forum 2026 on May 21

**SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced that the company will present at the BioStock Global Forum 2026 on May 21 in Lund, Sweden. The event provides an excellent platform to engage investors and potential partners to support our development strategy for pro-resolution therapeutics.**

During the event, SynAct Pharma's CBO, Mads Bjerregaard, will provide an update on the company's latest development of resomelagon and addressing expectations leading up to topline results of Phase 2b ADVANCE study in rheumatoid arthritis expected in June.

"With topline data from our Phase 2b ADVANCE study approaching we are at a pivotal point in the development of resomelagon and the demonstration of its application in newly diagnosed patients with rheumatoid arthritis. We are actively engaging with strategic partners to support our development strategy to have pro-resolution therapies like resomelagon addressing unmet need for millions of patients with autoimmune and acute inflammatory diseases," says Mads Bjerregaard, CBO at SynAct Pharma.

The BioStock Global Forum is premier event bringing together biotech, medtech, and health-tech innovators with global investors and strategic partners.

### **For further information, please contact:**

Jeppe Øvlesen  
CEO, SynAct Pharma AB  
Phone: + 45 2844 7567  
E-mail: [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

### **About SynAct Pharma AB**

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: <https://synactpharma.com/>.

### **Attachments**

[SynAct Pharma to present at the BioStock Global Forum 2026 on May 21](#)